Robin Geller, Baxter Healthcare Corporation, on the #Pharmacovigilance industry

Continuing with our series on the current pharmacovigilance industry we spoke with Robin Geller, Director of Risk Management and Safety Writing Global Pharmacovigilance, at Baxter Healthcare Corporation What is the biggest change that you are seeing in pharma's drug safety strategies at the moment? The continuing shift from submission of individual case reports to aggregate analysis, signal detection and risk …

Topics to be covered at #DrugSafety Europe

If you can't make our Drug Safety USA event taking place next week, why not check out our European event coming up in September? The brochure is due out in a few weeks but see below for a sneak preview of some of the presentations due to take place: In depth review of the new European pharmacovigilance legislation Operational implications …

Who has previously attended Drug Safety World?

  The World Drug Safety Congress Americas will provide you with the opportunity to meet and network with the big names in the industry. If you are thinking of attending but aren't sure who will be there, check out the list below of previous companies who have come to the event in the past.   If you are interested in …

Dr Brian Henry, Exec Direc, Pharmaceutical R&D, Pfizer discusses challenges for #pharma in drug development

We asked Dr Brian Henry, Executive Director, Pharmaceutical R&D, Pfizer some questions regarding the current challenges his organisation is facing. What challenges does your organisation face in implementing new approaches for increasing productivity of drug development? The increased understanding of the genetic basis for disease has opened up the opportunity to develop more specific and effective treatments for smaller patient …

Whitepaper Download – Managing Clinical Trials and Central Laboratory Services in China, by PPD

China's huge population and growing commitment to health care are predicted to make the country the world's second-largest consumer of pharmaceuticals by 2015. However, despite the size of the market, the large numbers of treatment-naïve patients, and the necessity of collecting clinical trial data patients in China before the Chinese State Food and Drug Administration (SFDA) will approve a drug …

Clinical Trials Benefit From New-Generation LIMS

Presenting on the above topic is Chamnong Ingsathit, Consultant, Labware, Thailand. He will be speaking at 5th Annual BioPharma Asia Convention 2012, held on 19th to 22nd March 2012 at Marina Bay Sands, Singapore. He will be conducting an on-floor seminar at Theatre 1 at 11:00 on the 20th of March. Here is a short abstract on what he will …

White Paper Download – Clinical Trials Benefit From Advanced LIMS

In this White Paper, Robin Longdin of LCG Bioscience and Nick Townsend of LabWare Europe discuss the introduction of a new-generation laboratory information management system (LIMS) into a busy Phase I clinical trials facility. Laboratory information management systems (LIMS) are widely used to automate laboratory processing and to assist with regulatory compliance. Organisations that installed LIMS many years ago are …